
Quarterly report 2025-Q3
added 11-06-2025
Organogenesis Holdings Net Debt 2011-2026 | ORGO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Organogenesis Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -131 M | -97.2 M | -73.6 M | -55.8 M | -31.8 M | 40.4 M | 20.3 M | -25.9 K | -1.04 M | 48.9 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 40.4 M | -131 M | -32.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
285 M | $ 3.47 | 4.37 % | $ 86.3 M | ||
|
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | ||
|
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B | ||
|
Cronos Group
CRON
|
-1.07 B | $ 2.65 | 2.52 % | $ 1.39 B | ||
|
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
338 M | $ 8.28 | 3.31 % | $ 424 M | ||
|
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.33 | 6.39 % | $ 46.8 M | ||
|
Neoleukin Therapeutics
NLTX
|
-101 M | - | - | $ 193 M | ||
|
Rockwell Medical
RMTI
|
691 K | $ 1.07 | 3.88 % | $ 25 M | ||
|
Bausch Health Companies
BHC
|
21.1 B | $ 5.17 | 3.4 % | $ 1.89 B | ||
|
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | ||
|
Solid Biosciences
SLDB
|
-38.7 M | $ 7.23 | 8.23 % | $ 633 M | ||
|
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | ||
|
Pacira BioSciences
PCRX
|
317 M | $ 23.36 | 0.67 % | $ 1.08 B | ||
|
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | ||
|
Evolus
EOLS
|
94.8 M | $ 4.45 | 0.34 % | $ 287 M | ||
|
Perrigo Company plc
PRGO
|
3.1 B | $ 9.63 | -0.1 % | $ 1.33 B | ||
|
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | ||
|
Tilray
TLRY
|
14.4 M | $ 6.99 | 4.95 % | $ 4.32 B | ||
|
Sundial Growers
SNDL
|
-28.4 M | $ 1.39 | 1.09 % | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 2.35 | 0.43 % | $ 2.92 M | ||
|
Relmada Therapeutics
RLMD
|
-2.5 M | $ 6.57 | 7.7 % | $ 259 M | ||
|
OrganiGram Holdings
OGI
|
90.7 M | $ 1.41 | 5.22 % | $ 402 M | ||
|
SCYNEXIS
SCYX
|
-19.1 M | $ 0.91 | 0.57 % | $ 45.4 M | ||
|
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | ||
|
Veru
VERU
|
-20.9 M | $ 2.33 | 1.75 % | $ 314 M | ||
|
Viatris
VTRS
|
16.8 B | $ 13.65 | 2.13 % | $ 16.4 B | ||
|
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.62 | 8.98 % | $ 10.8 M | ||
|
cbdMD
YCBD
|
-521 K | $ 0.79 | 0.86 % | $ 3.41 M | ||
|
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | ||
|
Canopy Growth Corporation
CGC
|
193 M | $ 1.0 | 3.86 % | $ 108 M | ||
|
Assertio Holdings
ASRT
|
29.1 M | $ 17.53 | 6.18 % | $ 112 M | ||
|
TherapeuticsMD
TXMD
|
3.68 M | $ 2.4 | 4.8 % | $ 25.1 M | ||
|
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | ||
|
Harrow Health
HROW
|
178 M | $ 35.82 | 1.76 % | $ 1.32 B | ||
|
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M |